Germany · Delayed Price · Currency is EUR EXACT Therapeutics AS Statistics
Total Valuation
FRA:56F has a market cap or net worth of EUR 8.87 million. The enterprise value is 3.93 million.
| Market Cap | 8.87M |
| Enterprise Value | 3.93M |
Important Dates
The next estimated earnings date is Thursday, December 25, 2025.
| Earnings Date | Dec 25, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
| Current Share Class | 63.26M |
| Shares Outstanding | n/a |
| Shares Change (YoY) | +50.98% |
| Shares Change (QoQ) | +69.11% |
| Owned by Insiders (%) | 16.90% |
| Owned by Institutions (%) | 12.37% |
| Float | 16.23M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| PB Ratio | 1.56 |
| P/TBV Ratio | 1.56 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -0.65 |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | -0.53 |
Financial Position
The company has a current ratio of 2.70, with a Debt / Equity ratio of 0.01.
| Current Ratio | 2.70 |
| Quick Ratio | 2.02 |
| Debt / Equity | 0.01 |
| Debt / EBITDA | n/a |
| Debt / FCF | -0.00 |
| Interest Coverage | -12.66 |
Financial Efficiency
Return on equity (ROE) is -169.68% and return on invested capital (ROIC) is -99.86%.
| Return on Equity (ROE) | -169.68% |
| Return on Assets (ROA) | -65.00% |
| Return on Invested Capital (ROIC) | -99.86% |
| Return on Capital Employed (ROCE) | -101.98% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -506,430 |
| Employee Count | 12 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -85.73% in the last 52 weeks.
| Beta (5Y) | n/a |
| 52-Week Price Change | -85.73% |
| 50-Day Moving Average | 0.12 |
| 200-Day Moving Average | 0.18 |
| Relative Strength Index (RSI) | 38.51 |
| Average Volume (20 Days) | n/a |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -5.81M |
| Pretax Income | -6.08M |
| Net Income | -6.08M |
| EBITDA | -5.64M |
| EBIT | -5.81M |
| Earnings Per Share (EPS) | -0.12 |
Balance Sheet
The company has 4.92 million in cash and 29,787 in debt, giving a net cash position of 4.89 million.
| Cash & Cash Equivalents | 4.92M |
| Total Debt | 29,787 |
| Net Cash | 4.89M |
| Net Cash Per Share | n/a |
| Equity (Book Value) | 5.70M |
| Book Value Per Share | 0.09 |
| Working Capital | 4.81M |
Cash Flow
In the last 12 months, operating cash flow was -7.03 million and capital expenditures -428,251, giving a free cash flow of -7.46 million.
| Operating Cash Flow | -7.03M |
| Capital Expenditures | -428,251 |
| Free Cash Flow | -7.46M |
| FCF Per Share | n/a |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
FRA:56F does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -50.98% |
| Shareholder Yield | -50.98% |
| Earnings Yield | -68.54% |
| FCF Yield | -84.11% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | n/a |